To evaluate the efficacy of psilocybin-assisted therapy for cocaine use disorder (CUD) among adults in a pilot study context.
Key Findings:
Psilocybin-assisted therapy showed potential for improving abstinence and reducing relapse over 180 days post-treatment, indicating a need for further investigation.
Secondary outcomes related to substance use or functional recovery were not reported, limiting the understanding of overall treatment impact.
The study faced challenges due to lack of fidelity monitoring and the principal investigator being the sole therapist, raising concerns about treatment consistency.
Interpretation:
While initial findings suggest psilocybin may be beneficial for CUD, the lack of rigorous methodology and fidelity monitoring raises significant concerns about the reliability of the results and their applicability.
Limitations:
No a priori power analysis conducted, which limits the statistical validity of the findings.
Lack of fidelity monitoring in psychotherapy delivery raises questions about treatment integrity.
Exclusion of individuals with common comorbid conditions limits generalizability and applicability to the broader population.
Conclusion:
Further research is needed to validate the efficacy of psilocybin-assisted therapy, especially in diverse populations and those with co-occurring conditions, while considering practical challenges for implementation and the need for rigorous methodology.
A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.
